Trending Stocks: Yamana Gold, Inc. (NYSE:AUY), Cara Therapeutics Inc. (NASDAQ:CARA), WGL Holdings Inc. (NYSE:WGL), Epizyme, Inc. (NASDAQ:EPZM), Weis Markets, Inc. (NYSE:WMK)

Yamana Gold, Inc. (NYSE:AUY) belongs to Basic Materials sector. Its weekly performance is -8.45%. On last trading day company shares ended up $2.71. Yamana Gold, Inc. (NYSE:AUY) distance from 50-day simple moving average (SMA50) is -21.70%. YAMANA GOLD INC. (NYSE:AUY) declares a second quarter 2015 dividend of $0.015 per share. Shareholders of record at the close of business on June 30, 2015 will be entitled to receive payment of this dividend on July 14, 2015. The dividend is an “eligible dividend” for Canadian tax purposes.

Cara Therapeutics Inc. (NASDAQ:CARA) shares advanced 4.08% in last trading session and ended the day at $13.28. CARA return on assets is -31.90%. Cara Therapeutics Inc. (NASDAQ:CARA) quarterly performance is 21.50%. On 23 June, Cara Therapeutics, Inc. (NASDAQ:CARA), announced that it has completed enrollment in its Phase 2 proof-of-concept trial of its lead kappa opioid agonist, CR845, for the treatment of uremic pruritus (UP).

On 10 July, WGL Holdings Inc. (NYSE:WGL) shares advanced 0.86% and was closed at $54.88. WGL EPS growth in last 5 year was -3.00%. WGL Holdings Inc. (NYSE:WGL) year to date (YTD) performance is 3.00%. WGL Holdings Inc (NYSE:WGL) cash dividend payment of $0.4625 per share is scheduled to be paid on August 01, 2015.

Epizyme, Inc. (NASDAQ:EPZM) ended the last trading day at $23.42. Company weekly volatility is calculated as 6.90% and price to cash ratio as 3.95. Epizyme, Inc. (NASDAQ:EPZM) showed a weekly performance of 3.13%. Epizyme, Inc. announced that it has dosed the first patient in the phase 2 trial of its lead clinical candidate, tazemetostat (EPZ-6438) in patients with relapsed or refractory non-Hodgkin lymphoma (NHL). This five-arm study will enroll up to 150 patients with germinal center diffuse large B cell lymphoma (DLBCL) or follicular lymphoma, stratified into those expressing mutant EZH2 and those expressing wild type EZH2, as well as patients with non-germinal center DLBCL.

Weis Markets, Inc. (NYSE:WMK) shares increased 1.08% in last trading session and ended the day at $43.80. WMK Gross Margin is 27.20% and its return on assets is 4.60%. Weis Markets, Inc. (NYSE:WMK) quarterly performance is -9.33%. Weis Markets (NYSE: WMK) declared a quarterly dividend of $0.30 per share, or $1.2 annualized. The dividend will be payable on August 3, 2015, to stockholders of record on July 20, 2015, with an ex-dividend date of July 16, 2015.

Leave a Reply

Your email address will not be published. Required fields are marked *